KING PHARMACEUTICALS, INC.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2004

King Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

         
Tennessee
(State or other jurisdiction
of incorporation)		   0—24425
(Commission
File Number) 		  54-1684963
(IRS Employer
Identification Number)
     
501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)		   37620
(Zip Code)

Registrant’s telephone number, including area code: 423-989-8000

Not Applicable
(Former name or former address, if changed since last report)

 

 

     Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

     (c) Exhibits.

     The following exhibits are filed pursuant to Item 601 of Regulation S-K:

Exhibits:

     
Exhibit    
Number
   Description of Exhibit
99.1
  Press Release of King Pharmaceuticals, Inc. dated August 5, 2004.

Item 12. Results of Operation and Financial Condition

     On August 5, 2004, King Pharmaceuticals, Inc., a Tennessee corporation, issued a press release which announced its second quarter 2004 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

     The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
Date: August 5, 2004 KING PHARMACEUTICALS, INC.  
 
  By:   /s/ James R. Lattanzi    
    James R. Lattanzi   
    Chief Financial Officer